In today’s ACT Brief, we look at new evidence showing how targeted training can build research readiness at community cancer ...

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...

Discover how remote assessments, wearables, and digital technologies can decentralize data collection, reduce patient burden, and enable trials to reach more diverse and representative populations.

Explore how expanding clinical trials into community and nontraditional sites, simplifying protocols, and leveraging AI can ...

And the FDA has approved Amgen’s Uplizna for adults with antibody-positive generalized myasthenia gravis, adding a ...

See how combining human oversight with AI insights improves protocol authorship, site selection, and monitoring strategies, ...

For industry-sponsored trials in autoimmune inflammation therapeutic areas, the dominating indications include atopic ...

In today’s ACT Brief, we break down FDA’s new superiority requirement reshaping CAR-T development, examine Pfizer’s global ...

Explore how AI can optimize study design, speed patient recruitment, and streamline operational workflows to shorten ...

ACT: As new ICH GCP guidelines roll out, how are sponsors balancing the drive for innovation—especially in areas like CAR-T ...

As highly effective anti-obesity therapies emerge and regulatory expectations evolve, sponsors are adopting innovative trial designs, addressing long-term weight maintenance, monitoring lean mass ...

In today’s ACT Brief, we explore how stronger vendor–sponsor governance is speeding eCOA study startup, hear from AMR ...